PB 12 of 2014

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 2)

National Health Act 1953

___________________________________________________________________________

I, Kim Bessell, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated 23 February 2014

KIM BESSELL

Assistant Secretary

Pharmaceutical Access Branch

Principal Pharmacy Advisor

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________

1              Name of Instrument

(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No.2).

(2)                This Instrument may also be cited as PB 12 of 2014.

2             Commencement

                This Instrument commences on 1 March 2014.

3              Amendments to PB 79 of 2011

                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

Schedule 1                   Amendments

[1]     Schedule 1 Part 1, entry for Carboplatin in the form ‘Solution for I.V. injection 150 mg in 15 mL’ with manner of administration Injection:

omit:      

[2]     Schedule 1 Part 1, entry for Cisplatin in the forms ‘I.V. injection 100 mg in 100 mL’ and ‘I.V. injection 50 mg in 50 mL’ with manner of administration Injection:

omit:      

[3]     Schedule 1 Part 1, entry for Epirubicin in the form ‘Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL’ with manner of administration Injection/Intravesical:

omit:

[4]     Schedule 1 Part 1, entry for Fludarabine in the form ‘Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL’ with manner of administration Injection:

omit:

[5]     Schedule 1 Part 1, entry for Gemcitabine in the forms ‘Powder for I.V. infusion 2 g (as hydrochloride)’ and ‘Powder for I.V. infusion 200 mg (as hydrochloride)’  with manner of administration Injection:

omit:      

[6]     Schedule 1 Part 1, entry for Gemcitabine in the form ‘Solution concentrate for I.V. infusion 1000 mg (as hydrochloride) in 100 mL’ with the manner of administration Injection :

omit:

insert:

[7]     Schedule 1 Part 1, entry for Gemcitabine in the form ‘Solution concentrate for I.V. infusion 200 mg (as hydrochloride) in 20 mL’ with the manner of administration Injection :

omit:

insert:

[8]     Schedule 1 Part 1, entry for Irinotecan in the form ‘I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL’ with the manner of administration Injection :

omit:      

[9]     Schedule 1 Part 1, entry for Mitozantrone in the form ‘Injection 20 mg (as hydrochloride) in 10 mL’ with the manner of administration Injection :

omit:      

[10]  Schedule 1 Part 1, entry for Oxaliplatin in the form ‘Solution concentrate for I.V. infusion 50 mg in 10 mL’ with the manner of administration Injection :

omit:      

[11]  Schedule 1 Part 1, entry for Paclitaxel in the form ‘Solution concentrate for I.V. infusion 100 mg in 16.7 mL’ with the manner of administration Injection :

omit:      

[12]  Schedule 1 Part 1, entry for Paclitaxel in the forms ‘Solution concentrate for I.V. infusion 100 mg in 16.7 mL’; ‘Solution concentrate for I.V. infusion 30 mg in 5 mL’ and ‘Solution concentrate for I.V. infusion 300 mg in 50 mL’ with the manner of administration Injection :

omit: